Background: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a type
| INTRODUCTION
Chronic rhinosinusitis (CRS) affects 11%-15% of the general population and causes a considerable socioeconomic burden. 1, 2 CRS is a heterogeneous inflammatory disease with two distinct clinical presentations based on pathophysiology and histology. 3 CRS without nasal polyposis is a mainly neutrophilic disease with local elevations in T helper type 1-derived cytokines, whereas CRS with nasal polyposis (CRSwNP) is characterized by type 2/T helper type 2 cell (Th2) inflammation, with marked infiltration of eosinophils and mast cells in the mucosa and polyp tissue. 4 Increased concentrations of eosinophil cationic protein (ECP; a marker of activated, degranulated eosinophils), eotaxins, total immunoglobulin E (IgE), and interleukin (IL)-4, IL-5, and IL-13 have been observed in the serum, plasma, and nasal polyp tissue of patients with CRSwNP. [5] [6] [7] Type 2 innate lymphoid cells 8, 9 and type 2/Th2 lymphocytes 10 accumulate in nasal polyps and mucosa of CRSwNP patients and secrete IL-4, IL-5, and IL-13, 11, 12 key drivers of type 2 inflammation, which also play roles in CRSwNP-associated diseases such as aspirin-exacerbated respiratory disease and asthma. Another feature of CRSwNP is the presence of mucosal B cells and plasma cells that secrete IgE, 13, 14 providing evidence for local IL-4-modulated switching of Ig class.
The current standard of care for CRSwNP is focused on controlling inflammation and, depending on disease severity, consists of intranasal corticosteroid spray or drops, nasal saline lavage, short courses of oral corticosteroids, antibiotics, and functional endoscopic sinus surgery. 2 A subgroup of patients with CRSwNP does not respond well to the current standard of care and has a rapid relapse of polyp regrowth after surgery. 15 Blocking the underlying immunological pathomechanisms with monoclonal antibodies (mAbs) targeting IL-4, IL-5, and IL-13 has shown promising results in these patients. 16, 17 In clinical trials, omalizumab, a mAb that recognizes IgE, significantly reduced nasal polyp size and showed improvement in both upper and lower airway functions in patients with CRSwNP; 18 mepolizumab, a mAb targeting IL-5, significantly reduced nasal polyp size and computed tomography (CT) scores in patients with severe nasal polyposis. 19 IL-4 and IL-13 are key drivers of type 2-mediated inflammation;
these cytokines have structural similarities and signal via the IL-4
Type II heterodimeric receptor complex composed of IL-4 receptor alpha (IL-4Rα) and IL-13 receptor alpha 1 (IL-13Rα1 
| Study treatments
After 4 weeks of treatment with mometasone furoate nasal spray (MFNS; 100 mg/nostril twice daily), 60 patients were randomly allocated (1:1) to receive a 600 mg loading dose of dupilumab followed by 16 weeks of 300 mg dupilumab (n = 30) or matched placebo (n = 30). 32 MFNS was continued at a stable dose throughout the study, and inhaled asthma control therapies were allowed.
| Study outcomes
Primary and secondary endpoints in the overall population have been previously reported 32 and are described in detail in Table S1 . 
| Measurement of cytokines, total IgE, and ECP concentrations in tissue homogenates
Analysis of biomarker levels in the tissue of nasal polyps was carried out as previously described. 5 To create tissue homogenates, the tissue was disrupted at 50 Hz for 2 minutes with the Tissue Lyser LT (Qiagen Benelux, Antwerp, Belgium), and 1 mL 0.9% NaCl in the presence of cOmplete ™ , an EDTA-free protease inhibitor (Roche Diagnostics Belgium, Vilvoorde, Belgium), per 0.1 g of tissue was added. Homogenates were centrifuged at 1800 × g for 10 minutes at 4°C. Supernatants were removed and stored at −25°C until analysis.
All supernatants were analyzed for the presence of cytokines, chemokines, ECP, and total IgE. Total IgE and ECP levels were measured using the UniCAP system (Thermo Fisher Scientific, Phadia, Groot-Bijgaarden, Belgium) according to manufacturer instructions.
Cytokines were assayed using the Luminex Performance Assay (IL-4, successfully biopsied was small (n = 4), dupilumab treatment effect on biopsy biomarkers was assessed as change from baseline, analyzed using the Wilcoxon matched-pairs signed-rank test, in addition to a comparison of dupilumab vs placebo, which was analyzed using the Mann-Whitney U test. P < 0.05 was considered statistically significant.
| RESULTS

| Study patients
The baseline clinical characteristics of the overall study population were similar to those of patients with biopsy data available, except for numerical differences between posterior rhinorrhea in the morning ( Table 1, Table S2 ). Baseline demographics and/or clinical characteristics were also comparable between treatment groups in both the overall population and biopsy subgroup, except for numerical differences between total IgE in serum, and ECP and total IgE in nasal secretions (overall population), and posterior rhinorrhea in the morning (biopsy subgroup) ( Table 1, Table S2 ). The majority of patients in both the placebo (80%) and dupilumab (83.3%) groups completed the study. 32 Fourteen patients provided biopsies at baseline, 12 of whom also provided biopsies at Week 16.
| Safety
Safety outcomes were previously reported in the overall population of this study. 32 The most common treatment-emergent adverse events were mild-to-moderate nasopharyngitis, injection-site reactions, and headache, and were reported more frequently in the dupilumab treatment group vs placebo.
| Nasal secretion analysis
Dupilumab treatment was associated with overall decreases in nasal secretion concentrations of eotaxin-3, total IgE, and ECP (mean changes from baseline shown in Figure 1 ). vs −3.07 [4.6] ng/mL; P = 0.6364). In the dupilumab group, the mean absolute total IgE, ECP, and eotaxin-3 concentrations in nasal secretions at baseline were numerically higher than in the placebo group and declined over time, reaching concentrations either similar to or lower than the placebo group at Week 16 (Table S3) 
| Clinical responses in biopsy subgroup
In the biopsy subgroup (and consistent with that previously reported for the overall study population 32 ), dupilumab significantly improved radiographic and patient-reported measures of disease activity after 16 weeks of treatment vs placebo, including the Lund-Mackay total score, percentage of maxillary sinus volume occupied by disease, SNOT-22 score, sinusitis symptom severity assessed by the visual analog scale, and sense of smell assessed by UPSIT, and significantly reduced circulating concentrations of total IgE and eotaxin-3 (P < 0.05 for all; Table 1 ). In this small subset of patients, improvements in bilateral endoscopic NPS, peak nasal inspiratory flow in the morning, and nasal congestion or obstruction in the morning and posterior rhinorrhea in the morning, as well as shifts in blood eosinophil counts and serum TARC on dupilumab, were not significantly different with dupilumab vs placebo ( Table 1) .
| Tissue homogenate analysis
Dupilumab treatment was associated with significantly lower total (Table S4) . Furthermore, significant differences in median changes from baseline with dupilumab vs placebo treatment at Week 16 were found for eotaxin-1 (P < 0.05), PARC (P < 0.01), and ECP (P < 0.01) (Figure 3) . No significant differences were found for IL-6, IL-33, SE-IgE, TARC, total IgE, eotaxin-2 and 3, IL1b, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, and IL-33 (Table S5) . Overall, no consistent modulation pattern was observed in the placebo group between baseline and end of treatment for any of these biomarkers in the tissue homogenates, with a limited sample size (n = 4) (Figures 2, 3 ).
| DISCUSSION
CRSwNP is characterized by a type 2-predominant eosinophilic endotype in most patients. The presence of high levels of total IgE 18, 19, 33, 34 However (with the exception of periostin), local reductions in IL-5, ECP, or total IgE levels in nasal secretions and homogenates were not demonstrated with these therapeutic agents. 34, 35 We recently reported that dupilumab, an IL-4Rα inhibitor that blocks IL-4 and IL-13 signaling, was well tolerated, reduced polyp size, and rapidly improved smell in patients with CRSwNP. 32 The post hoc analyses reported here were conducted to further investigate the local effects of dupilumab on eosinophilic inflammation and obtain more information on the relationship between local and serum levels of type 2 chemokines and total IgE in patients with CRSwNP.
Dupilumab treatment was associated with a significant decrease in biomarkers of type 2 inflammation, including total IgE and eotaxin-3, in nasal secretions, as well as a decrease in ECP that did not reach statistical significance, vs placebo. In nasal polyp homogenates, dupilumab significantly reduced total IgE, the chemokines eotaxin-2, eotaxin-3, and PARC, and ECP concentrations at Week 16 compared with baseline, and eotaxin-1, ECP, and PARC only when compared as mean changes from baseline at Week 16 vs placebo; similar trends were not observed with placebo. These data suggest that dupilumab not only reduces mucosal IgE production via antagonism of IL-4Rα signaling, but most likely also affects the eosinophil pathway locally via suppression of eosinophil chemokine release; this is consistent with prior observations of increased levels of total IgE, ECP, and eosinophils in nasal polyps that may respond to therapy. 5 We have previously reported that dupilumab markedly lowers total IgE and eotaxin-3 levels in the blood of patients with CRSwNP. 32 Thus, dupilumab demonstrates both systemic and local effects on these markers of type 2 inflammation in CRSwNP.
Eosinophil cationic protein is a cytotoxic ribonuclease produced and released by degranulating eosinophils. ECP concentrations are associated with the number of activated eosinophils in the blood. 
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CRSwNP. Eotaxin levels are elevated in CRSwNP and other allergic and eosinophilic diseases such as asthma and AD. 37 The eotaxin family consists of eotaxin-1 (CCL11), eotaxin-2 (CCL24), and eotaxin-3 (CCL26), all of which are potent chemotactic factors for eosinophils and other inflammatory cells that express their receptors, and are released from epithelial cells following exposure to IL-4 and IL-13. 38, 39 Eotaxins act on eosinophils and T lymphocytes to prolong the survival of eosinophils via the production and secretion of type 2-associated cytokines 37 and mediate transepithelial eosinophil migration and activation. 40, 41 Eotaxin-3, in particular, has been suggested to be an important recruiter of eosinophils in asthma, 42 eosinophilic esophagitis, 43 and nasal polyposis. 44 
